Results 211 to 220 of about 1,441,811 (290)

A Patient‐Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery

open access: yesAdvanced Science, EarlyView.
This study successfully establishes adamantinomatous craniopharyngioma (ACP) patient‐derived organoids (PDOs) that preserve the histopathological and genetic features of the original tumors. Through drug sensitivity assays and subsequent mechanistic analyses, the study demonstrates that Ceritinib exerts its inhibitory effects on ACP PDO growth by ...
Huarong Zhang   +15 more
wiley   +1 more source

CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target

open access: yesAdvanced Science, EarlyView.
CircSMEK1 is downregulated in MASH/HCC and predicts poor prognosis. It suppresses tumor progression by promoting hnRNPK ubiquitination and inhibiting the IGF2/PI3K/AKT axis, while its loss activates immunosuppressive cancer‐associated fibroblasts. Serum circSMEK1 serves as a non‐invasive diagnostic biomarker, and its restoration potently inhibits HCC ...
Peilan Guo   +15 more
wiley   +1 more source

Polish Paralympic Sports in the Opinion of Athletes and Coaches in Retrospective Studies. [PDF]

open access: yesInt J Environ Res Public Health, 2019
Sobiecka J   +5 more
europepmc   +1 more source

Microglial Deletion of Hrh4 Alleviates Alzheimer's Disease Pathologies by Enhancing Microglial Phagocytosis of Amyloid‐β and Tau

open access: yesAdvanced Science, EarlyView.
Histamine H4 receptor (H4R) antagonist VUF6002 mimics low‐dose X‐ray irradiation in aged Alzheimer's disease (AD) mice, enhancing microglial clearance of amyloid‐beta/hyperphosphorylated tau aggregates and restoring cognition. Microglial H4R deletion activates cAMP/TGF‐β1/Smad3 pathway, enhancing phagocytosis, while TGF‐β receptor 1 deletion abolishes ...
Yi‐Jun Xu   +5 more
wiley   +1 more source

Interferon‐Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
Triple‐negative breast cancer exhibits variable sensitivity to PRMT5 inhibition. Basal interferon signaling is identified as a key biomarker of response. PARP inhibition with olaparib induces IFN signaling, sensitizing resistant TNBC cells to PRMT5 inhibitors.
Ziwen Zhang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy